Bioengineered miR-328-3p modulates GLUT1-mediated glucose uptake and metabolism to exert synergistic antiproliferative effects with chemotherapeutics

MicroRNAs (miRNAs or miRs) are small noncoding RNAs derived from genome to control target gene expression.Recently we have developed a novel platform permitting high-yield production of bioengineered miRNA agents (BERA).This study is to produce and utilize novel fully-humanized BERA/miR-3’28-3p molecule (hBERA/miR-3’28) to delineate the role of miR-328-3p in controlling nutrient uptake essential for cell metabolism.We first demonstrated successful high-level expression of hBERA/miR-328 in bacteria and purification to high degree of homogeneity (>98%).Biologic miR-328-3p prodrug was selectively processed to miR-328-3p to suppress the growth of highly-proliferative human osteosarcoma (OS) cells.Besides glucose transporter protein type 1,gene symbol solute carrier family 2 member 1 (GUJTHSLC2A1),we identified and verified large neutral amino acid transporter 1,gene symbol solute carrier family 7 member 5 (LPAT1/SLC7A5) as a direct target for miR-3’28-3p.While reduction of LAT1 protein levels by miR-3’28-3p did not alter homeostasis of amino acids within OS cells,suppression of GLUT1 led to a significantly lower glucose uptake and decline in intracellular levels of glucose and glycolytic metabolite lactate.Moreover,combination treatment with hBERA/miR-3’28 and cisplatin or doxorubicin exerted a strong synergism in the inhibition of OS cell proliferation.These findings support the utility of novel bioengineered RNA molecules and establish an important role of miR-328-3p in the control of nutrient transport and homeostasis behind cancer metabolism.